Lexaria Bioscience (LEXX) Competitors $1.31 -0.04 (-2.96%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$1.31 0.00 (0.00%) As of 09/23/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEXX vs. ATYR, IRD, ANEB, ORMP, ADAG, IPA, VIRI, CRDL, HOWL, and OVIDShould you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include aTyr Pharma (ATYR), Opus Genetics (IRD), Anebulo Pharmaceuticals (ANEB), Oramed Pharmaceuticals (ORMP), Adagene (ADAG), ImmunoPrecise Antibodies (IPA), Virios Therapeutics (VIRI), Cardiol Therapeutics (CRDL), Werewolf Therapeutics (HOWL), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry. Lexaria Bioscience vs. Its Competitors aTyr Pharma Opus Genetics Anebulo Pharmaceuticals Oramed Pharmaceuticals Adagene ImmunoPrecise Antibodies Virios Therapeutics Cardiol Therapeutics Werewolf Therapeutics Ovid Therapeutics Lexaria Bioscience (NASDAQ:LEXX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends. Which has more volatility and risk, LEXX or ATYR? Lexaria Bioscience has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Do institutionals and insiders hold more shares of LEXX or ATYR? 13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 26.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 3.7% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has higher earnings and valuation, LEXX or ATYR? Lexaria Bioscience has higher revenue and earnings than aTyr Pharma. Lexaria Bioscience is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$460K55.70-$5.80M-$0.67-1.96aTyr Pharma$230K421.83-$64.02M-$0.80-1.24 Does the media favor LEXX or ATYR? In the previous week, aTyr Pharma had 36 more articles in the media than Lexaria Bioscience. MarketBeat recorded 36 mentions for aTyr Pharma and 0 mentions for Lexaria Bioscience. aTyr Pharma's average media sentiment score of 0.15 beat Lexaria Bioscience's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Overall Sentiment Lexaria Bioscience Neutral aTyr Pharma Neutral Is LEXX or ATYR more profitable? aTyr Pharma has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,849.19%. aTyr Pharma's return on equity of -93.69% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Lexaria Bioscience-1,849.19% -157.22% -133.69% aTyr Pharma N/A -93.69%-68.83% Do analysts rate LEXX or ATYR? Lexaria Bioscience presently has a consensus price target of $4.00, indicating a potential upside of 205.34%. aTyr Pharma has a consensus price target of $23.25, indicating a potential upside of 2,248.25%. Given aTyr Pharma's higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00aTyr Pharma 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14 SummaryaTyr Pharma beats Lexaria Bioscience on 10 of the 15 factors compared between the two stocks. Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXX vs. The Competition Export to ExcelMetricLexaria BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.41M$3.16B$5.76B$10.51BDividend YieldN/A2.36%5.53%4.57%P/E Ratio-1.9621.0476.0626.61Price / Sales55.70252.06472.8291.51Price / CashN/A46.3537.4661.85Price / Book2.739.7813.586.45Net Income-$5.80M-$52.73M$3.29B$271.57M7 Day Performance8.26%3.16%1.83%2.61%1 Month Performance65.24%4.69%4.02%7.28%1 Year Performance-58.01%16.37%77.05%29.60% Lexaria Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXLexaria Bioscience3.2659 of 5 stars$1.31-3.0%$4.00+205.3%-58.5%$26.41M$460K-1.967Positive NewsATYRaTyr Pharma2.5052 of 5 stars$1.04-1.4%$23.25+2,146.4%-44.1%$101.42M$230K-1.2953IRDOpus Genetics1.7812 of 5 stars$1.69-1.2%$7.33+333.9%N/A$101.25M$10.99M-0.8814ANEBAnebulo Pharmaceuticals1.6904 of 5 stars$2.48-0.2%$5.50+122.2%+10.4%$101.06MN/A-9.464ORMPOramed Pharmaceuticals0.3062 of 5 stars$2.45+4.5%N/A+7.1%$100.08M$1.34M-6.9710ADAGAdagene2.9219 of 5 stars$2.11+2.7%$7.00+232.5%-8.9%$99.44M$100K0.00260IPAImmunoPrecise Antibodies2.6417 of 5 stars$2.10+8.5%$4.00+90.9%+226.1%$96.68M$17.59M-3.0880Gap UpVIRIVirios Therapeutics0.2987 of 5 stars$5.01+4.1%$5.00-0.2%+2,567.4%$96.48MN/A-18.565News CoverageCRDLCardiol Therapeutics2.8325 of 5 stars$1.10-2.2%$8.00+630.6%-52.6%$94.96MN/A-3.2520News CoveragePositive NewsAnalyst RevisionHOWLWerewolf Therapeutics3.7278 of 5 stars$2.05+11.4%$8.00+290.2%-14.8%$94.84M$1.88M-1.2640Positive NewsGap UpOVIDOvid Therapeutics4.2194 of 5 stars$1.32+2.3%$3.10+134.8%+13.5%$93.87M$570K-2.4960 Related Companies and Tools Related Companies ATYR Competitors IRD Competitors ANEB Competitors ORMP Competitors ADAG Competitors IPA Competitors VIRI Competitors CRDL Competitors HOWL Competitors OVID Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEXX) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
